TLDR
- DNLI jumps 4.93% before a sharp 7.66% after-hours reversal
- Takeda exits DNL593 deal, handing Denali full program control
- DNL593 shows strong brain delivery in early clinical results
- Phase 1/2 trial completes enrollment with 40 participants
- Denali targets 2026 data release for key biomarker insights
Denali Therapeutics (DNLI) shares ended the session higher before a sharp reversal after hours following a major partnership update. The stock closed at $20.65, rising 4.93% during regular trading. However, it later dropped to $19.07 in after-hours trading, marking a 7.66% decline.
Denali Therapeutics Inc., DNLI
Denali Regains Control of DNL593 After Takeda Exit
Denali Therapeutics confirmed that Takeda ended its collaboration agreement for the DNL593 program. The decision followed internal strategic priorities rather than clinical concerns. Denali now holds full ownership of the therapy and its intellectual property.
The company originally partnered with Takeda to co-develop and commercialize DNL593 for neurodegenerative conditions. Denali led most development activities throughout the collaboration period. As a result, the transition to full control appears operationally aligned with its existing role.
The regained ownership strengthens Denali’s position in advancing its proprietary pipeline. The company can now independently manage development timelines and strategic direction. This shift also centralizes decision-making around the program’s future progress.
DNL593 Targets Frontotemporal Dementia With Promising Early Data
DNL593 focuses on treating frontotemporal dementia linked to progranulin deficiency, known as FTD-GRN. The therapy uses Denali’s Protein TransportVehicle platform to cross the blood-brain barrier. This approach supports targeted delivery of progranulin directly into the brain.
The ongoing Phase 1/2 trial includes 40 participants and has completed enrollment. Early findings from healthy volunteers showed dose-dependent increases in cerebrospinal fluid progranulin levels. These results indicate effective brain delivery and support the therapy’s mechanism.
The study reported no significant safety concerns during early evaluation stages. The therapy showed good tolerability across tested dose levels. Current data continues to support further clinical development of DNL593.
Pipeline Strategy and Upcoming Milestones Shape Outlook
Denali plans to release full biomarker data from the ongoing study by the end of 2026. This update will provide deeper insight into the therapy’s clinical potential. The company continues to position its TransportVehicle platform as a core innovation driver.
This platform enables delivery of therapeutic molecules across the blood-brain barrier. It supports multiple programs targeting neurodegenerative diseases with limited treatment options. Denali maintains a focused pipeline strategy centered on neurological disorders.
The after-hours decline reflects market reaction to the partnership termination despite unchanged clinical expectations. Denali retains full strategic control over DNL593’s future development. This development introduces a new phase of independent execution for the program.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
